comparison of sequential-concomitant hybrid to sequential therapy in h.pylori eradication rate

hybrid therapy in H.pylori

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201110312499N2

Enrollment

296

Registered

2011-12-02

Start date

2011-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PUD(H.PYLORI ERADICATION REGIMEN). GASTRIC ULCER,DUODENAL ULCER,PEPTIC ULCER DISEASE, GASRTRODUODENITIS

Interventions

Intervention 1: Intervention group: pantoprazole 40mg (BD) + Amoxicillin 1g (BD) + Clarithromycin 500mg (BD) and Tinidazole 500mg (BD) during the first 2 weeks. Intervention 2: Control group: pantopr

Treatment - Drugs

Intervention group: pantoprazole 40mg (BD) + Amoxicillin 1g (BD) + Clarithromycin 500mg (BD) and Tinidazole 500mg (BD) during the first 2 weeks

Control group: pantoprazole 40mg (BD) for 10 days + Amoxicillin 1g (BD) just during the first 5 days + Clarithromycin 500mg (BD) and Tinidazole 500mg (BD) just during the second 5 days

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age more than 18 years and less than 80 years with duodenal or gastric ulcers; duodenal or gastric erosions and helicobacter pylori positivity. Exclusion criteria: Previous history of receiving any H.pylori eradication regimen, Taking H2 blocker, proton pump inhibitor, Bismuth or Antibiotics during the 2 weeks prior to the study, Taking anticoagulants, ketoconazole or corticosteroids, History of gastric or esophageal surgery, Severe cardiovascular, pulmonary or endocrine disease, Renal failure, Hepatic diseases, Malignancies, Alcoholism, Pregnancy or breast feeding

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Helicobacter pylori eradication rate. Timepoint: 2 months after the completion of treatment course. Method of measurement: urease breath test.	—

Secondary

Measure	Time frame
Side effects of drugs. Timepoint: daily recording during and after the treatment course. Method of measurement: classifying as mild, moderate or severe side effects.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hafez Tirgar Fakheri

Mazandaran University of Medical Sciences

Hfakheri@mazums.ac.ir fakheri42@yahoo.com00981512261700 00989111521404 00981512264044

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026